Lupus Nephritis: Statement Analysis
Statements (a), (b), (c), and (e) are correct; statement (d) is false—lupus nephritis is highly treatable with multiple effective immunosuppressive regimens.
Detailed Analysis of Each Statement
(a) Female Predominance with 6:1 Ratio - CORRECT
Systemic lupus erythematosus and lupus nephritis predominantly affect women, though the exact ratio varies by population. The 6:1 female-to-male ratio is a reasonable approximation, though some studies report ratios ranging from 9:1 to 10:1 1. Recent pooled analysis of 831 females and 122 males (approximately 7:1 ratio) confirms this female predominance 2. The key clinical point is that males may present with more severe disease at diagnosis, including higher serum creatinine levels and increased renal activity indices 3, though long-term outcomes appear similar between sexes 2.
(b) At Least 50% Develop Nephritis - CORRECT
The lifetime incidence of lupus nephritis ranges from 20-60% depending on the population studied 1. Multiple guidelines confirm that approximately 40-50% of SLE patients develop kidney disease 4, 5. The 2024 KDIGO guideline specifically states "the reported lifetime incidence of lupus nephritis is 20-60%" 1, making the statement that "at least 50%" develop nephritis technically correct for certain populations, particularly those with higher-risk demographics (younger age, certain racial/ethnic groups).
(c) Immune-Complex-Mediated Disease - CORRECT
Lupus nephritis is definitively characterized as an immune complex-mediated glomerulonephritis 1, 6, 5. The 2024 KDIGO guideline explicitly describes it as "immune complex-mediated glomerulonephritis (GN) in the setting of SLE" 1. The pathogenic mechanism involves autoantibody production, immune complex formation and deposition in the kidneys, followed by local inflammation leading to organ damage 5, 7.
(d) Untreatable - FALSE
This statement is categorically incorrect. Lupus nephritis has multiple highly effective treatment options with established efficacy. The 2024 KDIGO guidelines recommend several first-line induction regimens 1:
- Mycophenolic acid analogs (MPAA) plus glucocorticoids (1B recommendation)
- Low-dose intravenous cyclophosphamide plus glucocorticoids (1B recommendation)
- Belimumab combined with either MPAA or cyclophosphamide (1B recommendation)
- MPAA plus calcineurin inhibitor when eGFR >45 ml/min/1.73m² (1B recommendation)
The 2020 EULAR/ERA-EDTA guidelines similarly recommend multiple effective regimens 4. Recent studies demonstrate complete remission rates of 61-83% at 6-12 months across different treatment protocols 8, 9. The goal of treatment is to preserve kidney function and reduce mortality associated with chronic kidney disease while minimizing medication toxicity 1.
(e) Low Complement Levels - CORRECT
Low complement levels (C3 and C4) are characteristic findings in lupus nephritis, reflecting complement system activation as part of the immune complex-mediated pathogenesis 1, 3. However, recent evidence reveals important nuances: complement levels have limited predictive value for assessing disease activity, particularly in Class V (membranous) lupus nephritis 10. The 2025 study found that while complement levels correlate somewhat with activity in Class III/IV disease, they show no correlation with activity indices in Class V disease 10. Despite these limitations in monitoring, low complement at presentation remains a characteristic laboratory finding.
Clinical Pitfalls
- Do not assume male patients have better prognosis—they may present with more severe renal dysfunction despite similar long-term outcomes 3, 2
- Do not rely solely on complement levels to assess disease activity, especially in membranous lupus nephritis; use comprehensive assessment including proteinuria, creatinine, and SLEDAI-2K 10
- Do not delay treatment based on incomplete serological profiles—the disease is highly treatable with multiple effective options 1, 4